Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity
Tóm tắt
Human papillomavirus (HPV) vaccines based on major capsid protein L1 are licensed in over 100 countries to prevent HPV infections. The yeast-derived recombinant quadrivalent HPV L1 vaccine, GARDASIL(R), has played an important role in reducing cancer and genital warts since its introduction in 2006. The L1 proteins self-assemble into virus-like particles (VLPs). VLPs were subjected to post-purification disassembly and reassembly (D/R) treatment during bioprocessing to improve VLP immunoreactivity and stability. The post-D/R HPV16 VLPs and their complex with H16.V5 neutralizing antibody Fab fragments were visualized by cryo electron microscopy, showing VLPs densely decorated with antibody. Along with structural improvements, post-D/R VLPs showed markedly higher antigenicity to conformational and neutralizing monoclonal antibodies (mAbs) H16.V5, H16.E70 and H263.A2, whereas binding to mAbs recognizing linear epitopes (H16.J4, H16.O7, and H16.H5) was greatly reduced. Strikingly, post-D/R VLPs showed no detectable binding to H16.H5, indicating that the H16.H5 epitope is not accessible in fully assembled VLPs. An atomic homology model of the entire HPV16 VLP was generated based on previously determined high-resolution structures of bovine papillomavirus and HPV16 L1 pentameric capsomeres. D/R treatment of HPV16 L1 VLPs produces more homogeneous VLPs with more virion-like antibody reactivity. These effects can be attributed to a combination of more complete and regular assembly of the VLPs, better folding of L1, reduced non-specific disulfide-mediated aggregation and increased stability of the VLPs. Markedly different antigenicity of HPV16 VLPs was observed upon D/R treatment with a panel of monoclonal antibodies targeting neutralization sensitive epitopes. Multiple epitope-specific assays with a panel of mAbs with different properties and epitopes are required to gain a better understanding of the immunochemical properties of VLPs and to correlate the observed changes at the molecular level. Mapping of known antibody epitopes to the homology model explains the changes in antibody reactivity upon D/R. In particular, the H16.H5 epitope is partially occluded by intercapsomeric interactions involving the L1 C-terminal arm. The homology model allows a more precise mapping of antibody epitopes. This work provides a better understanding of VLPs in current vaccines and could guide the design of improved vaccines or therapeutics.
Tài liệu tham khảo
Roldao A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM: Virus-like particles in vaccine development. Expert Rev Vaccines. 2010, 9: 1149-1176. 10.1586/erv.10.115.
Villa LL: HPV prophylactic vaccination: The first years and what to expect from now. Cancer Lett (N Y, NY, U S). 2011, 305: 106-112.
Kwak K-H, Yemelyanova A, Roden RBS: Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol. 2011, 23: 244-251. 10.1016/j.coi.2010.11.009.
Majewski S, Bosch FX, Dillner J, Iversen OE, Kjaer SK, Munoz N, Olsson SE, Paavonen J, Sigurdsson K, Bryan J, et al: The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol. 2009, 23: 1147-1155. 10.1111/j.1468-3083.2009.03266.x.
Bryan JT: Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine. 2007, 25: 3001-3006. 10.1016/j.vaccine.2007.01.013.
Frazer IH, Lowy DR, Schiller JT: Prevention of cancer through immunization: prospects and challenges for the 21st century. Eur J Immunol. 2007, 37: S148-S155. 10.1002/eji.200737820.
Frazer IH, Leggatt GR, Mattarollo SR: Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol. 2011, 29: 111-138. 10.1146/annurev-immunol-031210-101308.
Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL: Arrangement of L2 within the papillomavirus capsid. J Virol. 2008, 82: 5190-5197. 10.1128/JVI.02726-07.
Zhao Q, Wu S, Manger W, Gadam S: Process for making human papillomavirus virus-like particles with improved properties. US Patent 6,436,402. 2002
Buck CB, Thompson CD, Pang Y-YS, Lowy DR, Schiller JT: Maturation of papillomavirus capsids. J Virol. 2005, 79: 2839-2846. 10.1128/JVI.79.5.2839-2846.2005.
McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA: Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol. 1998, 72: 32-41.
Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, Shi L: Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci. 2006, 95: 2195-2206. 10.1002/jps.20696.
Salunke D, Caspar DLD, Garcea RL: Polymorphism in the assembly of polyomavirus capsid protein VP1. Biophys J. 1989, 56: 887-900. 10.1016/S0006-3495(89)82735-3.
Nguyen H, Reddy VS, Brooks CL: Invariant polymorphism in virus capsid assembly. J Am Chem Soc. 2009, 131: 2606-2614. 10.1021/ja807730x.
Nguyen H, Brooks CL: Generalized structural polymorphism in self-assembled viral particles. Nano Lett. 2008, 8: 4574-4581. 10.1021/nl802828v.
Shi L, Sings HL, Bryan JT, Wang B, Wang Y, Mach H, Kosinski M, Washabaugh MW, Sitrin R, Barr E: GARDASIL: Prophylactic human papillomavirus vaccine development-from bench top to bed-side. Clin Pharmacol Ther. 2007, 81: 259-264. 10.1038/sj.clpt.6100055.
Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA: Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology. 1996, 223: 174-184. 10.1006/viro.1996.0466.
Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, McClements WL, Ludmerer SW, Jansen KU: Hybrid Papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct hpv types. Virology. 2001, 291: 324-334. 10.1006/viro.2001.1220.
Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R, et al: Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccines. 2005, 1: 191-197. 10.4161/hv.1.5.2126.
Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, Nguyen M, Wang F, Wang N, Wang B, Wang Y, et al: Evaluation of the thermal stability of Gardasil. Hum Vaccines. 2006, 2: 147-154. 10.4161/hv.2.4.2989.
Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT: Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003, 10: 108-115.
Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT: Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol. 2010, 17: 818-827. 10.1128/CVI.00348-09.
Roden RBS, Armstrong A, Haderer P, Christensen ND, Hubbert NL, Lowy DR, Schiller JT, Kirnbauer R: Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol. 1997, 71: 6247-6252.
Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA: Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol. 2003, 77: 11625-11632. 10.1128/JVI.77.21.11625-11632.2003.
Cason J, Patel D, Naylor J, Lunney D, Shepherd PS, Best JM, McCance DJ: Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes. J Gen Virol. 1989, 70: 2973-2987. 10.1099/0022-1317-70-11-2973.
Wang D, Christensen N, Schiller JT, Dillner J: A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol. 1997, 78: 2209-2215.
Culp TD, Spatz CM, Reed CA, Christensen ND: Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology. 2007, 361: 435-446. 10.1016/j.virol.2006.12.002.
High K, Meng Y, Washabaugh MW, Zhao Q: Determination of picomolar equilibrium dissociation constants in solution by enzyme-linked immunosorbent assay with fluorescence detection. Anal Biochem. 2005, 347: 159-161. 10.1016/j.ab.2005.09.007.
Meng Y, High K, Wang Y, Washabaugh M, Zhao Q: Solution antigenicity analysis of human papillomavirus type 16 virus-like particles preparations by antibody binding IC50 and affinity constant determination. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States. 2004, BIOL-229
Dillner J, Dillner L, Utter G, Eklund C, Rotola A, Costa S, DiLuca D: Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames. Int J Cancer. 1990, 45: 529-535. 10.1002/ijc.2910450326.
Wang X, Wang Z, Christensen ND, Dillner J: Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. Virology. 2003, 311: 213-221. 10.1016/S0042-6822(03)00179-X.
Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS: Crystal structures of four types of human Papillomavirus L1 Capsid Proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem. 2007, 282: 31803-31811. 10.1074/jbc.M706380200.
Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME: Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods. 1985, 77: 305-319. 10.1016/0022-1759(85)90044-4.
Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS: Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology. 1996, 224: 477-486. 10.1006/viro.1996.0554.
Zhao Q, Towne V, Brown M, Wang Y, Abraham D, Oswald CB, Gimenez JA, Washabaugh MW, Kennedy R, Sitrin RD: In-depth process understanding of RECOMBIVAX HB((R)) maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Vaccine. 2011, 29: 7936-7941. 10.1016/j.vaccine.2011.08.070.
Zhao Q, Wang Y, Abraham D, Towne V, Kennedy R, Sitrin RD: Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. Biochem Biophys Res Commun. 2011, 408: 447-453. 10.1016/j.bbrc.2011.04.048.
Zhao Q, Allen MJ, Wang Y, Wang B, Wang N, Shi L, Sitrin RD: Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine. 2012, doi:10.1016/j.nano.2012.01.007
Dasgupta J, Bienkowska-Haba M, Ortega ME, Patel HD, Bodevin S, Spillmann D, Bishop B, Sapp M, Chen XS: Structural basis of oligosaccharide receptor recognition by human papillomavirus. J Biol Chem. 2011, 286: 2617-2624. 10.1074/jbc.M110.160184.
Wolf M, Garcea RL, Grigorieff N, Harrison SC: Subunit interactions in bovine papillomavirus. Proc Natl Acad Sci USA. 2010, 107: 6298-6303. 10.1073/pnas.0914604107.
Zhao Q, Guo HH, Wang Y, Washabaugh MW, Sitrin RD: Visualization of discrete L1 oligomers in human papillomavirus 16 virus-like particles by gel electrophoresis with Coomassie staining. J Virol Methods. 2005, 127: 133-140. 10.1016/j.jviromet.2005.03.015.
Sapp M, Fligge C, Petzak I, Harris JR, Streeck RE: Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J Virol. 1998, 72: 6186-6189.
Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT: Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccines FIELD Full Journal Title:Human Vaccines. 2007, 3: 109-115.
Modis Y, Trus BL, Harrison SC: Atomic model of the papillomavirus capsid. EMBO J. 2002, 21: 4754-4762. 10.1093/emboj/cdf494.
Rizk RZ, Christensen ND, Michael KM, Muller M, Sehr P, Waterboer T, Pawlita M: Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol. 2008, 89: 117-129. 10.1099/vir.0.83145-0.
Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E, Giffin J, Hesterberg L: Finestructure epitope mapping of antierythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin structure. Blood. 1996, 87: 2702-2713.
Park S, Park J, Ko J, Chen L, Meriage D, Crouse-Zeineddini J, Wong W, Kerwin B: Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci. 2009, 98: 1688-1699. 10.1002/jps.21546.
Leatherbarrow R: GraFit (5) Data Fitting Software. 2006, Horley Syrrey, UK: Erithacus Software limited
Suloway C, Pulokas J, Fellmann D, Cheng A, Guerra F, Quispe J, Stagg S, Potter CS, Carragher B: Automated molecular microscopy: the new Leginon system. J Struct Biol. 2005, 151: 41-60. 10.1016/j.jsb.2005.03.010.
Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D: Biol Crystallogr. 2004, 60: 2126-2132. 10.1107/S0907444904019158.
Murshudov GN, Vagin AA, Dodson EJ: Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D: Biol Crystallogr. 1997, 53: 240-255. 10.1107/S0907444996012255.